We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
Cap. Flow
+$1.08B
Cap. Flow %
13.6%
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$440M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$270M
3
AFIB
Acutus Medical Inc
AFIB
+$166M
4
ACET icon
Adicet Bio
ACET
+$95.1M
5
TBPH icon
Theravance Biopharma
TBPH
+$68.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$119M
2
CI icon
Cigna
CI
+$82.5M
3
NTRA icon
Natera
NTRA
+$64.2M
4
ALEC icon
Alector
ALEC
+$52.6M
5
GKOS icon
Glaukos
GKOS
+$46.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 0.63%
3 Technology 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PASG icon
26
Passage Bio
PASG
$14.9M
$91.3M 1.15%
348,145
– –
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$87.1M 1.09%
9,614,280
– –
ISRG icon
28
Intuitive Surgical
ISRG
$128B
$80M 1.01%
338,400
– –
ACET icon
29
Adicet Bio
ACET
$76.7M
$79.8M 1%
419,282
+376,154
+872% +$95.1M
CNC icon
30
Centene
CNC
$31.3B
$77.9M 0.98%
1,335,700
– –
AGIO icon
31
Agios Pharmaceuticals
AGIO
$2.09B
$77.3M 0.97%
2,207,321
+478,900
+28% +$21M
SRPT icon
32
Sarepta Therapeutics
SRPT
$1.6B
$75.7M 0.95%
539,049
-20,600
-4% -$3.13M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.2B
$73.1M 0.92%
2,921,967
– –
AUPH icon
34
Aurinia Pharmaceuticals
AUPH
$1.92B
$70M 0.88%
4,754,000
+3,557,653
+297% +$51.5M
XLRN
35
DELISTED
Acceleron Pharma
XLRN
$67.6M 0.85%
601,066
+473,566
+371% +$47.1M
KROS icon
36
Keros Therapeutics
KROS
$197M
$64.8M 0.81%
1,679,417
– –
EXEL icon
37
Exelixis
EXEL
$14B
$58.8M 0.74%
2,404,100
– –
LOGC
38
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$58.7M 0.74%
6,466,783
– –
DCPH
39
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$57.7M 0.73%
1,125,700
– –
CALC icon
40
CalciMedica
CALC
$11.9M
$56.9M 0.72%
+319,703
New +$66.7M
EW icon
41
Edwards Lifesciences
EW
$48.4B
$56.4M 0.71%
706,500
+176,100
+33% +$13.7M
ELVN icon
42
Enliven Therapeutics
ELVN
$3.78B
$55.3M 0.7%
679,976
– –
ELDN icon
43
Eledon Pharmaceuticals
ELDN
$260M
$54.4M 0.68%
176,851
– –
NSTG
44
DELISTED
NanoString Technologies, Inc.
NSTG
$52.9M 0.66%
1,183,100
-9,300
-0.8% -$361K
CRSP icon
45
CRISPR Therapeutics
CRSP
$4.63B
$52.7M 0.66%
630,004
-67,520
-10% -$5.99M
EHTH icon
46
eHealth
EHTH
$43.2M
$50.4M 0.63%
638,558
– –
TELA icon
47
TELA Bio
TELA
$30.4M
$50.1M 0.63%
3,027,542
– –
PGNY icon
48
Progyny
PGNY
$2.46B
$49.3M 0.62%
1,675,500
+1,334,496
+391% +$36.8M
MGTX icon
49
MeiraGTx Holdings
MGTX
$1.06B
$49.2M 0.62%
3,713,820
– –
ATRC icon
50
AtriCure
ATRC
$2.01B
$49M 0.62%
1,228,189
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2020 Portfolio in Review

As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.

  • OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
  • OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
  • OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
  • OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
  • OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
  • OrbiMed opened 28 new positions and closed 20 in Q3 2020.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.